Pyrimidine PDE10 inhibitors
US9062059B2 · kind B2 · utility
2Cited by
1References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 2012 |
| Grant date | Jun 23, 2015 |
| Priority date | — |
| Expiry date | Aug 20, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/506
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.